Emerging role of metabolic reprogramming in the immune microenvironment and immunotherapy of thyroid cancer
Open Access
- 26 November 2024
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 144, 113702
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Gansu Province (17JR5RA272)
- Natural Science Foundation of Gansu Province (22JR5RA923)
This publication has 161 references indexed in Scilit:
- Hypoxia expedites the progression of papillary thyroid carcinoma by promoting the CPT1A‐mediated fatty acid oxidative pathwayDrug Development Research, 2024
- Thyroid CancerJAMA, 2024
- AKR1C3 silencing inhibits autophagy‐dependent glycolysis in thyroid cancer cells by inactivating ERK signalingDrug Development Research, 2024
- Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinomaVirchows Archiv, 2021
- Lipid Metabolism in Tumor-Associated Natural Killer Cells2021
- Synergistic activity of everolimus and 5‐aza‐2′‐deoxycytidine in medullary thyroid carcinoma cell linesMolecular Oncology, 2017
- Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progressionCellular and Molecular Life Sciences, 2015
- Dichloroacetate improves immune dysfunction caused by tumor‐secreted lactic acid and increases antitumor immunoreactivityInternational Journal of Cancer, 2013
- Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c‐Jun activationInternational Journal of Cancer, 2011
- Adiponectin is a negative regulator of antigen‐activated T cellsEuropean Journal of Immunology, 2011